![Global Cancer Diagnostics Market](https://res.cloudinary.com/devmoveo/image/upload/v1706083544/skyquest/report/phpRGeA7D.jpg)
Report ID: SQMIG35J2078
Report ID:
SQMIG35J2078 |
Region:
Global |
Published Date: August, 2024
Pages:
157
|
Tables:
149 |
Figures:
78
In April 2024, QIAGEN introduced QIAcuity dPCR PanCancer Kits which enable researchers to utilise QIAcuity dPCR system of QIAGEN to simultaneously detect multiple hallmark mutations of EGFR and BRAF with extraordinary sensitivity.
In June 2023, FDA granted its approval for POSLUMA by Blue Earth Diagnostics. It's a high-affinity radio hybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent with which it is possible to image accurately and precisely to detect and localize prostate cancer with potential therapeutic applications.
In April 2023, Quest Diagnostics acquired Haystack Oncology. The objective of this was to expand their suite of services in Minimal Residual Disease Testing; an initiative concentrated on colorectal, breast and lung cancer only at the outset however aimed at later encompassing other types too. It was mainly intended to improve patient outcomes by enhancing prompter MRD detection after treatment.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35J2078